Wyeth is now a wholly owned subsidiary of Pfizer

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Wyeth is now a wholly owned subsidiary of Pfizer sits in the top decile of US sponsors by registered trial count (#177 of 15,742 sponsors by registered trial count).

167 total trials none currently recruiting 139 completed early-phase tilt top decile by trial count

Wyeth is now a wholly owned subsidiary of Pfizer: 167 sponsored US clinical trials, none currently recruiting.

Wyeth is now a wholly owned subsidiary of Pfizer sponsors 167 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 139 completed. 53 of these trials are in Phase 3-4 (later-stage) and 102 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 5 trials.

Top-decile sponsor footprint

Wyeth is now a wholly owned subsidiary of Pfizer ranks in the top decile of sponsors by registered trial count (#177 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 48/100

139 of 167 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (83.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

167 total, page 3 of 4

COMPLETED Phase 3

Study Evaluating Pantoprazole in Children With Gastroesophageal Reflux Disease (GERD)

NCT00300755
COMPLETED Phase 1

Study Evaluating the Safety of HCV-796 in Subjects With Liver Disease and in Healthy Adults

NCT00314054
COMPLETED Phase 3

Study Evaluating the Pharmacokinetics of Venlafaxine ER and Desvenlafaxine SR in Healthy Subjects

NCT00329186
COMPLETED Phase 1

Study Evaluating the Effects of Multiple Oral Doses of ERB-041 on Cardiac Repolarization in Healthy Subjects

NCT00316459
COMPLETED Phase 3

Study Evaluating the Effects of DVS SR and Paroxetine on the Pharmacokinetics of Desipramine in Healthy Subjects

NCT00329147
COMPLETED Phase 2

Study Evaluating the Safety and Efficacy of ERB-041 on Reduction of Symptoms Associated With Endometriosis in Reproductive-Aged Women

NCT00318500
COMPLETED Phase 3

Study Evaluating B-Domain Deleted Recombinant Factor VIII (BDDrFVIII, ReFacto AF) in Patients With Hemophilia A Undergoing Elective Major Surgery

NCT00243659
COMPLETED Phase 3

Open Label Safety Study of Enteric-Coated Spheroid Suspension in Infants Aged Less Than 12 Months With Presumed Gastroesophageal Reflux Disease (GERD)

NCT00868296
TERMINATED Phase 3

Study Evaluating Desvenlafaxine Succinate Sustained-release (DVS SR) in Adult Outpatients With Pain Associated With Diabetic Peripheral Neuropathy

NCT00283842
COMPLETED Phase 1

Study Evaluating IMA-638 in Asthma

NCT00339872
COMPLETED Phase 3

Study Evaluating Desvenlafaxine Sustained-Release (DVS-SR) in Adult Outpatients With Major Depressive Disorder

NCT00277823
COMPLETED Phase 2

Study Evaluating SCA-136 in Subjects With Acute Exacerbations of Schizophrenia

NCT00265551
COMPLETED Phase 3

Study Evaluating Pantoprazole Sodium Enteric-Coated Spheroid Suspension In Infants With Presumed GERD

NCT00259012
TERMINATED Phase 2

Study Evaluating GAP-486 in Heart Rhythm

NCT00137293
TERMINATED Phase 2

Study Evaluating GAP-486 on Heart Rhythm in Patients With Coronary Artery Disease

NCT00137332
COMPLETED Phase 2

Study Evaluating Lecozotan SR in Mild to Moderate Alzheimer's Disease (AD)

NCT00151398
COMPLETED Phase 3

Study Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Vasomotor Symptoms Associated With Menopause

NCT00238732
COMPLETED Phase 3

Study Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Symptoms Associated With Menopause

NCT00234819
COMPLETED Phase 1

Study Comparing Premarin® Vaginal Cream Versus Premarin® Oral Tablets in Atrophic Vaginitis

NCT00167921
TERMINATED

Study Evaluating Metabolic Syndrome in Subjects Undergoing Gastric Bypass Bariatric Syndrome

NCT00283374
COMPLETED Phase 4

Study Comparing Tigecycline Versus Ceftriaxone Sodium Plus Metronidazole in Complicated Intra-abdominal Infection

NCT00195351
COMPLETED Phase 3

Study Evaluating Pantoprazole in Children With GERD

NCT00141817
COMPLETED Phase 2

Study Evaluating ERB-041 With Methotrexate in Rheumatoid Arthritis

NCT00141830
COMPLETED Phase 3

Study Evaluating Conjugated Estrogen Cream for Atrophic Vaginitis

NCT00137371
COMPLETED Phase 3

Study Evaluating Combination of Levonorgestrel (LNG) and Ethinyl Estradiol (EE) in Premenstrual Dysphoric Disorder

NCT00128934
COMPLETED Phase 4

Study Evaluating the Effect of Sirolimus on Non-Melanoma Skin Cancer in Kidney Transplant Recipients

NCT00129961
TERMINATED Phase 1

Study Evaluating TTI-237 in Advanced Malignant Solid Tumors.

NCT00195325
TERMINATED Phase 1

Study Evaluating Vaccine in Adults With HIV

NCT00195312
COMPLETED Phase 3

Study to Establish Bioequivalence of ReFacto AF (BDDrFVIII) With Advate (FLrFVIII) in Hemophilia A

NCT00141843
COMPLETED Phase 3

Study Evaluating Levonorgestrel/Ethinyl Estradiol (LNG/EE) in PMS

NCT00161681
TERMINATED Phase 2

Study Evaluating GAP-486 in Non-sustained Ventricular Tachycardia

NCT00124891
COMPLETED Phase 3

Study Evaluating Bifeprunox in Bipolar Depression

NCT00134459
COMPLETED Phase 3

Study Comparing a Pantoprazole Formulation to the Currently Marketed Tablet for GERD and Erosive Esophagitis

NCT00195208
COMPLETED Phase 3

Study Evaluating Bifeprunox in Bipolar Depression

NCT00245973
TERMINATED Phase 3

Study Comparing Sirolimus With Cyclosporine in a Calcineurin Inhibitor (CNI)-Free Regimen in Kidney Transplant Recipients

NCT00137345
COMPLETED Phase 2

Study Evaluating Etanercept in Moderate to Severe Asthma

NCT00141791
TERMINATED Phase 1

Study Evaluating TTI-237 in Advanced Malignant Solid Tumors

NCT00195247
COMPLETED

Study Evaluating Temsirolimus in Advanced Stage Squamous Cell Carcinoma of the Head & Neck

NCT00195299
COMPLETED Phase 2

Study Evaluating SRA-333 in Mild to Moderate Alzheimer's Disease (AD)

NCT00151333
COMPLETED

Study to Describe the Allergic Reactions to Factor IX in Patients With Hemophilia B

NCT00195221
COMPLETED Phase 1

Study Evaluating MYO-029 in Adult Muscular Dystrophy

NCT00104078
COMPLETED Phase 2

Study Evaluating ERB-041 in Endometriosis in Reproductive-Age Women

NCT00110487
COMPLETED Phase 1

Study Evaluating Vaccine in Adults With HIV

NCT00195234
COMPLETED Phase 1

Study Evaluating CMD-193 in Advanced Malignant Solid Tumors

NCT00161642
COMPLETED Phase 4

Study Comparing Etanercept and Methotrexate vs. Methotrexate Alone in Rheumatoid Arthritis

NCT00195494
COMPLETED Phase 1

Study Evaluating Pneumococcal Vaccine in Healthy Infants

NCT00205803
TERMINATED Phase 3

Study Evaluating CCI-779 and Letrozole in Post-menopausal Women With Breast Cancer

NCT00083993
COMPLETED NA

An Open Label Exploratory Study in Newly Diagnosed Prostate Cancer Patients

NCT00235794
COMPLETED Phase 3

Study Evaluating the Safety & Efficacy of DVS-223 SR for Relief of Vasomotor Symptoms Associated With Menopause

NCT00421031
COMPLETED Phase 3

Study Evaluating Tigecycline Versus Imipenem/Cilastatin in Hospital-Acquired Pneumonia

NCT00080496
← Previous Page 3 of 4 Next →

Phase Distribution

PhaseTrial count
Phase 1 74
Phase 2 28
Phase 3 43
Phase 4 10

Therapeutic Areas

Healthy 5
Gastroesophageal Reflux 2
Depression 2
Skin Diseases, Bacterial 1
Peptic Ulcer Hemorrhage 1
Vaccines, Pneumococcal 1
Bacterial Pneumonia 1
Vasomotor System 1
Pneumococcal Infections 1
Arthritis, Rheumatoid 1

How the Wyeth is now a wholly owned subsidiary of Pfizer early-phase archive is shaped

167 indexed studies, none listed as recruiting (0% open); 139 completed (83%).

Phase mix: 53 late (III/IV) vs 102 early (I/II) (early-phase heavy).

Top condition: Healthy (5 trials), 9 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Wyeth is now a wholly owned subsidiary of Pfizer: archived-pipeline peers nationwide

Peers matched on 167 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Wyeth is now a wholly owned subsidiary of Pfizer sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 050100150200 0%5%10%15%20% Total trials Recruiting share Wyeth is now a wholly owned subsidiary of PfizerTeva Branded Pharmaceutical Products R&DAstellas Pharma Global DevelopmentBausch Health AmericasSeattle Children's Hospital10xBio22nd Century Group23andMe3-C Institute for Social Development
Wyeth is now a wholly owned subsidiary of Pfizer sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Wyeth is now a wholly owned subsidiary of Pfizer sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 167 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Wyeth is now a wholly owned subsidiary of Pfizer page

167 registered trials is a research-attention snapshot, not an endorsement of Wyeth is now a wholly owned subsidiary of Pfizer or any single study.

  • None of Wyeth is now a wholly owned subsidiary of Pfizer's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Healthy is the condition Wyeth is now a wholly owned subsidiary of Pfizer studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Wyeth is now a wholly owned subsidiary of Pfizer pipeline card: 167 registered trials from official public datasets.Report a data error.